DRUG TRANSPORTERS IN THE INTESTINE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 512

30. Tamai I, Nakanishi T, Nakahara H, Sai Y, Ganapathy V, Leibach FH, Tsuji A. 1998.
Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter
PepT1. J Pharm Sci 87(12):1542-1546.
31. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon
GL. 1998. 5 -Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed
by the intestinal PEPT1 peptide transporter. Pharm Res 15(8):1154-1159.
32. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW,
Meier PJ. 1995. Molecular and functional characterization of an organic anion transporting
polypeptide cloned from human liver. Gastroenterology 109(4):1274-1282.
33. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic
anion-transporting polypeptides mediate transport of opioid peptides across blood-brain
barrier. J Pharmacol Exp Ther 294(1):73-79.
34. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular iden-
tification and characterization of novel members of the human organic anion transporter
(OATP) family. Biochem Biophys Res Commun 273(1):251-260.
35. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB.
2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to
decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71(1):11-20.
36. Su Y, Zhang X, Sinko PJ. 2004. Human organic anion-transporting polypeptide OATP-A
(SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the
vectorial transport of saquinavir in Hep G2 cells. Mol Pharm 1(1):49-56.
37. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger
K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B)
and its functional comparison with three other OATPs of human liver. Gastroenterology
120(2):525-533.
38. Hunter J, Hirst BH, Simmons NL. 1991. Epithelial secretion of vinblastine by human
intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. Br J
Cancer 64(3):437-444.
39. Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein-
mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm
Res 10(5):743-749.
40. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. 1993. Functional expres-
sion of P-glycoprotein in apical membranes of human intestinal Caco-2 cells: kinetics
of vinblastine secretion and interaction with modulators. J Biol Chem 268(20):14991-
14997.
41. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for
evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18(12):1660-1668.
42. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. 1989. The
three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in
normal mouse tissues. Mol Cell Biol 9(3):1346-1350.
43. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol
CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. 1994. Disruption of the
mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to
increased sensitivity to drugs. Cell 77(4):491-502.
44. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk
MA, Voordouw AC, Spits H, van Tellingen O, et al. 1997. Normal viability and altered